$1.65
+0.00 (+0.00%)
Open$1.69
Previous Close$1.65
Day High$1.69
Day Low$1.62
52W High$3.10
52W Low$1.33
Volume—
Avg Volume626.0K
Market Cap236.13M
P/E Ratio—
EPS$-0.40
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+457.6% upside
Current
$1.65
$1.65
Target
$9.20
$9.20
$6.27
$9.20 avg
$10.38
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 21.56M | 14.33M | 53.79M |
| Net Income | -55,629,421 | -33,277,819 | 2.31M |
| Profit Margin | -258.1% | -245.2% | 4.3% |
| EBITDA | -54,198,752 | -34,223,206 | 4.13M |
| Free Cash Flow | — | — | 1.88M |
| Rev Growth | +50.5% | +50.5% | +4.8% |
| Debt/Equity | 0.32 | 0.32 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |